Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 23, 2024 4:51pm
156 Views
Post# 35841737

RE:RE:RE:Company buyout price vs share price.

RE:RE:RE:Company buyout price vs share price.

Notable, not sure why you find the need to attack me?
im on the same page/ boat/ team you are.
I believe Pela & ONC has huge potential & upside.
in broader sense, I do not disagree with any of your posts. 

I just do like to look at different points of reference.
back to de risking. With the added biomarker requested & further trial results....Onc is worth a lot more now than a year ago. They have added shareholder value.
Most do not appreciate that concept & equate shareholder value with share price.
Two years ago, they had MBc in the line to become phase 3.
now they have MBc, pancreatic, both with fast track approval.
that has value......added value.
So either the SP will catch up to where it should be, or the company will be bought.
A parnership announcement would rapidly accelerate the trading price.

im not arguing your points. 
please don't view my details of corporate takeover as anything against Onc.
all I'm saying is.....when the deal is done it will be based on available financial data, that shareholders will be able to read & vote for or against.
management would give its opinion.
The third party auditors would give theirs. 

What won't happen is a lowball transaction, just because the SP is down.
That is a longer story for another day.
" hostile takeover"....
The vey hint of  that would send the sp skyward.
I do not know the potential upside. The downside was stated years ago, requiring an offer starting with a B.
Adding in recent activities, inflation & now two ++ possible uses of Pela..,could be mutiple uses if we add in CAR-T & unexplored immunotherapy, I'd say the absolute lowest would be $2.5 billion.
highest?
like you said, companies with less proven history have been bought out for mutiple billions.
Few remember or even care. Just after tye A.N. Licensing deal, there was a lot of talk about a buyout.
even to the point Matt commented, " we need to wait until after the summer, when lawyers come back from vacation"
That deal never made it to a vote. 

It involved 90%++ dillution, loss of control, meaning company xx could cancel Pela at any time. & was under the "B" figure.
Most  things worth having are worth the wait.
Regading " trusting" Andrew G?
Again anything he or others claim to be, need to be documented.
The B.O.D. Also gets first view of any negotiations.
other than that. Never met the guy. Can't judge either way.

 

 

<< Previous
Bullboard Posts
Next >>